Cellbion Co

Cellbion Co AAQS

The The AAQS of Cellbion Co (308430.KQ) as of Oct 23, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Cellbion Co has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Cellbion Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Cellbion Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2021
2.00 KRW
Jan 1, 2022
2.00 KRW
Jan 1, 2023
2.00 KRW
Jan 1, 2024
2.00 KRW
Jan 1, 2025
2.00 KRW
The Cellbion Co AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellbion Co Stock analysis

What does Cellbion Co do? Cellbion Co Ltd generates revenue through the manufacture and sale of pharmaceuticals, including innovative diagnostic and therapeutic new drugs developed by the company. The firm also sells generic prescription drugs and provides contract development and manufacturing organization (CDMO) services for clinical trial drugs. Additionally, the company produces cosmetic products under its own brand. The primary customers are healthcare providers, hospitals, and pharmaceutical companies seeking drug development and manufacturing solutions. The company's product segments include pharmaceuticals, generic prescription drugs, CDMO services, and cosmetics. Key buyers are healthcare institutions, pharmaceutical firms, and consumers purchasing cosmetics. Cellbion Co Ltd targets the Korean market with its domestic operations, focusing on both B2B and B2C segments through its diverse product portfolio. Cellbion Co Ltd's revenue streams are derived from the sale of pharmaceuticals, generic drugs, CDMO services, and cosmetic products. The company's business model emphasizes innovation in drug development alongside traditional pharmaceutical manufacturing, with a focus on serving the domestic Korean healthcare sector and expanding its CDMO capabilities for global clinical trials. Cellbion Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellbion Co stock

The AAQS of Cellbion Co is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Cellbion Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Cellbion Co

All Key Metrics — Cellbion Co